Evidence map›Paper›PMID 34187105›Full record

ArticleArhiv za higijenu rada i toksikologiju2021

Prevalence of five pharmacologically most important

Stojko Vidović, Ranko Škrbić, Miloš P Stojiljković, Vanja Vidović, Jelena Bećarević, Svjetlana Stoisavljević-Šatara, Nela Maksimović

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arhiv za higijenu rada i toksikologiju, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Major Allele Frequencies inJournal of personalized medicine · 2025
    Review
  2. Association ofBalkan journal of medical genetics : BJMG · 2024
    Article
  3. Article
  4. The Diversity ofThe application of clinical genetics · 2024
    Article
  5. Article
  6. International journal of general medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Stojko VidovićUniversity of Banja Luka Faculty of Medicine, Department of Human Genetics, Banja Luka, Bosnia and Herzegovina.
Ranko ŠkrbićUniversity of Banja Luka Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Banja Luka, Bosnia and Herzegovina.
Miloš P StojiljkovićUniversity of Banja Luka Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Banja Luka, Bosnia and Herzegovina.
Vanja VidovićUniversity of Banja Luka Faculty of Medicine, Department of Human Genetics, Banja Luka, Bosnia and Herzegovina.
Jelena BećarevićUniversity of Banja Luka Faculty of Medicine, Centre for Biomedical Research, Laboratory for Molecular Biology and Genetics, Banja Luka, Bosnia and Herzegovina.
Svjetlana Stoisavljević-ŠataraUniversity of Banja Luka Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Banja Luka, Bosnia and Herzegovina.
Nela MaksimovićUniversity of Belgrade Faculty of Medicine, Institute of Human Genetics, Belgrade, Serbia.
University of Banja Luka · BAUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzymes of the cytochrome P450 superfamily play a critical role in phase I drug metabolism. Among them, CYP2C9 and CYP2C19 are clinically important, as they can mediate severe toxicity, therapy failure, and increased susceptibility to cancer and other diseases caused by chemicals. The aim of this study was to determine the prevalence of pharmacologically most important allelic variants of the

Indexed as

Aryl Hydrocarbon HydroxylasesAllelesBosnia and HerzegovinaCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9HumansPolymorphism, GeneticPrevalenceAryl Hydrocarbon HydroxylasesCYP2C19 protein, humanCYP2C9 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9cytochrome P450 enzymesenzimi citokroma 450farmakogenetikapharmacogeneticspolimorfizam alelapolymorphic allele

Identifiers

PMID34187105
PMCPMC8265196
OpenAlexW3173619445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.